A Phase 1/2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Relapsed/Refractory Solid Tumors Harboring a Mutation in KIT or PDGFRA